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Abstract 
 
Introduction: The Safety Pharmacology Society (SPS) has conducted a survey of its 
membership to identify industry practices related to testing considered in the Comprehensive In 
vitro Proarrhythmia Assay (CiPA). Methods: Survey topics included nonclinical approaches to 
address proarrhythmia issues, conduct of in silico studies, in vitro ion channel testing methods 
used, drugs used as positive controls during the conduct of cardiac ion channel studies, types of 
arrhythmias observed in non-clinical studies and use of the anticipated CiPA ion channel assay. 
Results: In silico studies were used to evaluate effects on ventricular action potentials by only 
15% of responders. In vitro assays were used mostly to assess QT prolongation (95%), cardiac 
Ca2+ and Na+ channel  blockade (82%) and QT shortening or QRS prolongation (53%). For de-
risking of candidate drugs for proarrhythmia, those assays most relevant to CiPA including cell 
lines stably expressing ion channels used to determine potency of drug block were most 
frequently used (89%) and human stem cell-derived or induced pluripotent stem cell 
cardiomyocytes (46%).  Those in vivo assays related to general proarrhythmia derisking include 
ECG recording using implanted telemetry technology (88%), jacketed external telemetry (62%) 
and anesthetized animal models (53%). While the CiPA initiative was supported by 92% of 
responders, there may be some disconnect between current practice and future expectations, 
as explained. Discussion: Proarrhythmia liability assessment in drug development presently 
includes study types consistent with CiPA. It is anticipated that CiPA will develop into a 
workable solution to the concern that proarrhythmia liability testing remains suboptimal.  
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1. Introduction 
A need to seek understanding of mechanisms leading to drug-induced arrhythmias, with a view 
to better predicting drug-induced proarrhythmia with fewer false positives, has resulted in the 
development of the comprehensive in vitro proarrhythmia (CiPA) assay (Huang et al., 2016). 
Several biomarkers of ventricular repolarization-associated proarrhythmia risk have been 
considered in drug safety testing over the last few decades including QT prolongation (Stramba-
Badiale et al., 1997; Authier et al., 2010), QT dispersion (Day et al., 1990), early after-
depolarizations (Cranefield & Aronson, 1988) and TRIaD (triangulation, reverse use-
dependence, instability and dispersion of repolarization) (Hondeghem et al., 2001, Lawrence et 
al., 2008). Advocating the use of multiple in vitro ion channels in drug safety evaluation has 
emerged as an important strategy to assess the proarrhythmia liability of drug candidates during 
early stages of development (Kramer et al., 2013). While cell lines with stable heterologously 
expressed ion channels have been used as testing tools for decades, an increasing interest in 
the validation and application of human stem cell derived cardiomyocytes for proarrhythmia risk 
assessment is apparent (Guo et al., 2013; Navarrete et al., 2013; Qu et al., 2013; Qu et al., 
2015; Himmel, 2013; Kirby et al., 2016). Nonetheless, several factors have been shown to 
modulate ion channel voltage clamp study results (e.g., IC50 values) including the experimental 
temperature, the physicochemical nature of the drug studied, the voltage protocol used and 
whether the drug is actively perfused or static in the experimental chamber (Luo & Guthrie, 
2005).  Thus, numerous modifications have been proposed to optimize manual and automated 
patch clamp studies (Hamill et al., 1981; Wakefield et al., 2002; Lepple-Wienhues et al., 2003; 
Sigworth & Klemic, 2005; Brüggemann et al., 2006; Polonchuk, 2012; Comley, 2014; 
Obergrussberger et al., 2015). As an unfortunate consequence, a lack of consistency in testing 
protocols and study designs is present across laboratories within the pharmaceutical industry 
and CROs. Yet, nonclinical models for assessing proarrhythmia liability remain the cornerstone 
of regulatory drug safety testing and establishing best practices and careful evaluation of the 
translational value of the data obtained remains a priority (Hammond et al., 2001; Redfern et al., 
2003). Since their inception, in silico models have also gained considerable complexity 
regarding their ability to generate cardiac action potentials since they integrate species 
differences with respect to ion channel profiles with in vitro data (Mirams et al., 2011; O’Hara & 
Rudy, 2012; Okada et al., 2015; Rodriguez et al., 2015).  In the clinical arena, novel approaches 
to replace standard thorough QT (TQT) studies have been developed and are being 
implemented for use in marketing authorization submissions (Shah et al., 2016; Cavero et al., 
2016). More recently, dissection of the T wave into early and late phases of repolarization 
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(Johannesen et al., 2014; Vicente et al., 2015) has enabled a mechanistic evaluation of the 
proarrhythmia liability of drugs using clinical ECG data. Thus, proarrhythmia liability assessment 
is advancing at an accelerated pace from application of in silico modeling to clinical safety 
testing. As the regulatory paradigm for proarrhythmia liability assessment is evolving (Vincente 
et al., 2016), reviewing current testing practices as they relate to drug development was 
undertaken by the SPS and the results are summarized herein.   
2. Methods 
This survey was distributed by the SPS to 887 safety pharmacologists, toxicologists and 
pharmacologists working globally in the pharmaceutical industry, at CROs, regulatory agencies, 
academia or the technology provider industry.  Survey topics included (a) nonclinical 
approaches to address proarrhythmia issues, (b) conduct of in silico studies, (c) in vitro ion 
channel testing methods used, (d) drugs used as positive controls during the conduct of cardiac 
ion channel studies, (e) types of arrhythmias observed in non-clinical studies and (f) use of the 
anticipated CiPA ion channel assay.  Survey questions are reported in the results section 
together with the percentages of the answers. 
3. Results 
All results are presented as the percentage of the total number of responses received per 
question. Results are presented with all affiliations combined. In addition, we show the 
percentage of the 887 scientists who were asked that responded to each question (i.e., the 
response rate).  
3.1 Study Survey Demographics 
Scientists (n=887) from various fields of expertise (Fig. 1A) and geographic locations (Fig. 1B) 
were invited to participate in the survey and 85 (or 10%) responded. Of the 85 responders, a 
preponderance was from Europe (46%), followed by North America (38%) and Asia (17%). 
Responders originated from diverse business organizations (Fig. 1C) and company sizes (Fig. 
1D) with 57% employed at companies with >1000 employees. Thus, one cannot exclude the 
potential that multiple responders from the same organization may have contributed to this 
survey (an issue that was not quantified in the responses) despite a request that only one 
response be provided from the same organization.  Most responders were employed by 
pharmaceutical companies, followed by CROs and biopharmaceutical companies (Fig. 1C). The 
survey identified many interesting facts including the primary therapeutic areas that were 
pursued by the various companies (Fig 1E).  Oncology (74%) and neurology (68%) were the 
therapeutic indications frequently targeted for drug development followed by cardiovascular 
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(62%), inflammation (58%), metabolic diseases (51%), infectious disease (39%) and lastly, 
rare/orphan diseases (36%).  When asked, 60% of responders were involved with the design, 
conduct, interpretation, or review of in silico assays (Fig. 1F) and the response rate increased to 
87% for those involved in the conduct of in vitro ion channel assays (Fig. 1G). A majority (61%) 
of responders reported that their company developed small molecules (new chemical entities; 
NCE) while 27% of responders worked for institutions developing large molecules/biologics. 
3.2 Approaches that address Proarrhythmia & CiPA Related Drug Testing: Survey 
Results 
The most frequent (75%) nonclinical approach used to address proarrhythmia issues by 
responders was to conduct a battery of in vitro (i.e., binding and ion channel electrophysiology 
studies, etc.) and in vivo CV safety pharmacology assays to screen drug candidates and 
establish a risk profile during the drug discovery phase of development (Table 1). Conduct of 
“fit-for-purpose” nonclinical safety pharmacology tests based on an integration of observations 
derived from chemistry structure-activity relationships (SAR), toxicology study findings and other 
scientific considerations (e.g., drug indication, drug class, pharmacology, 
pharmacokinetics/pharmacodynamics etc.) was reported to be used by 31% of responders. 
When asked which assays were used in the last 5 years to assess cardiac/cardiovascular 
effects, the responses were analyzed in terms of those in vitro assays with potential application 
to CiPA method implementation and included cell lines stably expressing ion channels for 
determination of drug block potency (89%), ion channel binding assays (57%), human stem cell-
derived or induced pluripotent stem cell cardiomyocytes (iPSC-CM) (46%) and hERG channel 
trafficking (42%) and isolated tissue bath preparations (41%).  Those cardiac/cardiovascular 
assays/models currently used to evaluate cardiac safety include ECG recordings using 
implanted telemetry systems (88%) followed by jacketed external telemetry (JET) (62%), 
anesthetized animal models (53%), cardiac action potential recordings using e.g., Purkinje 
fibers (51%), isolated Langendorff hearts (38%) and isolated cardiac wedge preparations (18%), 
with both proarrhythmia animal models and Zebrafish assays used by 12% of responders 
(Table 2). 
 
3.2.1 Conduct of In Silico Assays 
One third of responders frequently used in silico studies to evaluate drug effects on IKr (‘hERG’ 
assays) while 35% of them had never used in silico studies for this purpose (Table 3). Only 15% 
of responders reported frequently using in silico studies to evaluate drug effects on the cardiac 
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action potential and 39% of responders had never used in silico studies at their company. Non-
cardiac drug safety evaluations that were reportedly using in silico models included genetic 
toxicity evaluations and the study of effects on other cardiac ion channels. When in silico studies 
were used, assays were reported to be conducted as part of the early discovery safety study 
assessment by a large proportion of responders (43%); however, 44% report that in silico 
modeling is not used at their respective companies (Table 4, panel A). 
3.2.2 In Vitro Ion Channel Electrophysiology Assays 
When asked to describe the timing of conduct of in vitro ion channel electrophysiology assays, 
most responders (80%) reported using in vitro assays during conduct of early safety frontloading 
(or discovery) phase of investigation before complete nonclinical data was obtained (Table 4, 
panel B). In vitro assays were most frequently used to assess QT prolongation (95%). Cardiac 
Ca2+ (82%) and Na+ channel blockade (82%), QT shortening (53%) and QRS prolongation 
(53%) were also reported as common applications of in vitro assays (Fig. 2). Only 33% of 
responders reported using in vitro assays to assess positive or negative cardiac inotropic 
effects, the remainder likely did not conduct such assessments. When establishing the IC50 
values for ion channel blockade most responders (37%) reported using four (4) test article 
concentrations (Fig. 3). A minority (36/85 or 42%) reported calculating confidence intervals for 
the IC50 values determined using in vitro ion channel assays (Fig. 4). Many responders (59%) 
reported that their company had abandoned a pharmacophore due to an inability to eliminate 
the potential for IKr blockade (Fig. 5).  However, of the 59% reporting only 10% frequently report 
abandoning a pharmacophore due to an inability to eliminate hERG channel blockade.  
Interestingly, 22% state that although hERG channel block may not be eliminated chemically 
they have not discontinued development of the pharmacophore. A majority (82%) also reported 
that in vitro ion channel testing procedures include the use of a positive control in each study 
(Table 5) with the assays performed at either room temperature (71%) or at physiological 
temperature (58%). Washout data was obtained by a minority of responders (43%). Automated 
(75%) or manual (71%) patch clamp systems were used by a similar proportion of responders 
with 48% conducting in vitro assays to Good Laboratory Practice (GLP). 
 
As expected, IKr/Kv11.1 (91%), ICa,L/Cav1.2 (80%), INa/Nav1.5 (77%) and IKs/Kv7.1 (53%) were 
the most frequently interrogated cardiac ion channels when used in stably expressed cell lines 
(Table 6). Although not as frequent, IKur/Kv1.5 (29%), Ito,f/Kv4.3 (22%), IK1/Kir2.1-2.3 (22%) and 
If/HCN4 (20%) were also evaluated. Drugs used as positive controls that were most frequently 
tested in the validation/qualification of each cardiac ion channel assay included E-4031 (65%), 
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verapamil (62%), nifedipine (59%), dofetilide (59%), cisapride (56%), flecainide (53%) and 
terfenadine (52%) (Table 7). Note that because of survey responders being from both the 
pharmaceutical industry and CRO’s, some compounds referenced in this table may have been 
reported by both if such studies were contracted out and conducted by CRO study director 
scientists.  Similarly, positive control drugs that were used frequently for cardiac ion channel 
studies in order to interpret and compare the IC50 values obtained for NCE’s also included a 
range of K+, Ca2+ and Na+ channel blockers such as E-4031 (79%), verapamil (72%), 
terfenadine (69%), dofetilide (67%), nifedipine (64%), flecainide (62%), cisapride (58%), 
quinidine (57%) and sotalol (55%) (Table 8). One third of responders (34%) estimated the 
variability (i.e., the range from lowest to highest value obtained) in IC50 values to be <25% while 
22% indicated that outcome variability was not formally evaluated and 24% did not know the 
level of variability of their assays (Table 9). A majority of responders (66%) used a 
supramaximal concentration of their positive control drug when conducting an in vitro ion 
channel study in order to determine whether the assay responded appropriately whereas half 
(49%) used a concentration of the positive control in the range of its IC50 value to assess 
sensitivity (Table 10). Most (79%) always used the same positive control drug in their ion 
channel assay whereas a minority selected positive controls to include a comparator/similar 
drug to the compound being tested (22%) while only 13% used a positive control drug based on 
the chemistry of the compound being tested.  Only 7% used a positive control based on the 
therapeutic indication of the compound to test (7%) (Table 11). 
3.2.3 Arrhythmias 
When asked whether drug-induced arrhythmias were encountered in the conduct of non-clinical 
studies only 22-44% of responders provided some indication of their observation (Table 12). Of 
the types of drug-induced arrhythmias queried, PVCs were most frequently reported for the 
standard CV safety model using dogs (80%); however, PVCs were also observed in NHP 
(59%), rabbit (29%) and guinea pigs (17%) (Table 12). Ventricular tachycardia was most 
frequently observed in dogs (79%) followed by NHP (58%) and rabbits (39%).  AVB was 
another common arrhythmia reported (77%) in drug studies involving the use of dogs. 
Responders also observed drug-induced ventricular fibrillation most frequently in dogs (55%) 
and NHP (55%).  Note that the dog and NHP are the most frequently used non-clinical safety 
pharmacology species thus there is a likely increased propensity for observations of various 
arrhythmia’s developing when NCE’s are tested in these species. 
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3.2.4 Human stem cells derived or iPSC cardiomyocytes 
Human stem cell derived or iPSC-CM were considered by most responders as a valuable 
addition to the spectrum of proarrhythmia screening assays (75%); however, only 26% 
considered such assays as an economically valuable addition to the safety study arsenal of 
non-clinical studies (Table 13). While 21% of responders considered human stem cell derived or 
iPSC-CM representative of adult cardiomyocytes and provide reliable data as a nonclinical 
safety assay, an equal number (19%) considered that these cells expressed relevant 
endogenous cardiac ion channels in culture to provide reliable data.  Remarkably, only 17% of 
responders consider that human stem cell derived or iPSC-CM could replace cell lines that 
stably express human cardiac ion channels. 
 
When responders were asked to estimate the predictivity for clinical responses (e.g., study 
findings from conduct of the Thorough QT (TQT) study) of the nonclinical safety assays used in 
the integrated risk assessment, only 21% selected 75-90% while only 15% selected >90% 
(Table 14).  21% of respondents do not know the estimated predictivity for clinical responses of 
the non-clinical safety assays used while 40% did not formally evaluate predictivity. 
3.2.5 CiPA 
Currently most responders view the ion channel portion of CiPA as a screening tool (56%) that 
is likely to be used primarily at the lead development stage (42%) of the drug development 
spectrum.  Only 34% would consider including it as a component of the first-in-human (FIH) 
regulatory submission package (Table 15) while 17% consider the CiPA ion channel assay as a 
requirement strictly indicated by the regulatory agencies (i.e., it currently would be only 
conducted as a check box exercise).  Note, however, that 13% of responders currently do not 
know how they would anticipate using the CiPA ion channel assays in drug development. 
4. Discussion 
The present survey aimed to identify current strategies that are used by those in the 
pharmaceutical industry, in particular safety pharmacologists, for non-clinical safety testing as 
they relate to proarrhythmia liability assessment.  In addition, a focus was placed on assays that 
are currently under evaluation within the CiPA initiative. The geographic region that contributed 
the largest number of responses was Europe. This proportion contrasts with prior SPS surveys 
(Friedrichs et al., 2005; Lindgren et al., 2008; Authier, 2016, Authier, 2013) for which North 
America was the predominant region. The percentage of responders involved in the 
development of small molecules reached 61%, which likely reflects a selection bias whereby 
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scientists developing NCE’s are more likely to be involved in proarrhythmia liability testing. It 
should be noted that CiPA is currently considered for small molecule proarrhythmia liability 
assessment.  
A pre-established battery of assays to screen drug candidates was used by most (75%) 
responders. This is perhaps somewhat surprising given that the common perception within SP 
testing is that approaches are taken in which studies are tailored with regard to indication, 
risk/benefit considerations and other factors such as whether the molecule is a biological or 
NCE (Pugsley et al., 2008). However, as has been pointed out previously, in the case of NCEs, 
potency in these assays has little to do with therapeutic class (Redfern et al., 2003).  Amongst 
available assays, cell lines with stably expressed ion channels and telemetry acquired ECG 
were used by most (89% and 88% of responders, respectively). Other assays had varying 
degrees of utilization which likely reflects historical practices within each organization, the 
perceived proarrhythmic risk of the drug candidate (i.e., science driven selection of 
proarrhythmia assays) based upon therapeutic area and the validation data available to support 
the added value of a given test as part of the overall risk assessment. As expected, given that 
CiPA is an emerging drug safety screening paradigm that is not yet fully validated, application of 
in silico assessment was not widely implemented. At present, in silico assays were most 
frequently reported (43%) to be used early in drug discovery. When in vitro assays were used, 
screening for IKr block remained the most frequent application followed by assessment of the 
effects on cardiac action potentials (Pollard et al., 2010; Valentin 2010; Valentin et al. 2010). 
This likely reflects the ‘hERG-centric’ approach to proarrhythmia testing which has prevailed 
within SP for well over a decade, consistent with issuance of ICH S7B (US FDA, 2005). As 
shown in Table 4B, in vitro assays, when used, were conducted early in drug discovery (i.e., 
frontloaded) during drug development.  In vitro assays were predominantly used to assess 
potential effects of drugs on cardiac cellular electrophysiology processes (Table 2).  
A majority (59%) reported that their company had abandoned at least one 
pharmacophore (or potential ‘toxicophore’) based on data obtained from assays characterizing 
drug-mediated blockade of IKr. This is an interesting finding that supports the rationale for the 
CiPA paradigm, originally proposed as the next logical step in drug proarrhythmia testing 
(Gintant et al., 2015; Fermini et al. 2016). As such, efforts are underway to provide a clear 
roadmap in the evaluation of the cardiac ion channel assays involved and provide oversight with 
regard to validation of a standardized testing strategy (Sager et al., 2014; Colatsky et al. 2016; 
Crumb et al., 2016).  
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In vitro ion channel assays are sensitive to experimental study conditions and data 
interpretation benefits from the inclusion of positive control drug(s). Most (81%) reported 
including a positive control agent in each study. A majority (71%) reported conducting in vitro 
ion channel assays at room temperature, which could reflect the current inability of some 
automated patch clamp systems to control experimental temperature. Potential differences in 
the predictive value of assays conducted at physiological or room temperatures are not fully 
characterized (Zhou et al., 1998) and the optimal testing conditions remain an open agenda 
item as CiPA efforts progress.  
Testing for drug effects on a panel of cardiac ion channels is required for a mechanistic 
prediction of the net effect of a drug on the ventricular action potential. The various cardiac ion 
channels were assessed in the following order of importance by responders: 
Kv11.1>Cav1.2>Nav1.5>Kv7.1>Kv1.5>Kv4.3>Kir2.1-2.3. These results suggest that the strategy 
to evaluate the proarrhythmic risk of an NCE can differ significantly amongst safety 
pharmacologists. The well characterized contribution of individual ionic currents to the genesis 
of the ventricular action potential has yet to produce a validated, integrated in silico 
proarrhythmia liability assay. 
Understanding the need to properly evaluate the proarrhythmic risk of a NCE is imperative 
to safety pharmacologists.  It should be recognized that the incidence of nearly all arrhythmia 
types (apart from heritable channelopathy related arrhythmias) increases with age (Chow et al., 
2012). Arrhythmias are the most common cause of sudden cardiac death (SCD) in patients with 
hypertrophic or dilated cardiomyopathy (O'Mahony et al., 2013; Wu et al., 1999) and ischaemic 
heart disease (Huikuri et al., 2001). Concurrent to this, it needs to be recognized that the use of 
prescription drugs also increases with age (Qato et al., 2016) which positions drug-induced 
arrhythmia as a serious safety concern. However, the susceptibility of the young animal 
population to spontaneous arrhythmia (Gauvin et al., 2009) notably differs from that observed in 
an older patient population, albeit limited studies are conducted to characterize spontaneous 
arrhythmias in standard laboratory animals of normal health at any age.  Rather, such studies, 
primarily academic in nature, involve development of arrhythmias by simulating pathology, e.g., 
by coronary artery ligation (Cheung et al., 1993; Hagerty et al., 1996). Unfortunately, the 
sensitivity of pre-clinical safety models to drug-induced arrhythmia development has been 
erroneously perceived to be lower than the sensitivity in the human population placing additional 
pressure on development of alternate arrhythmia risk assessment methods. This is easily 
illustrated by the fact that the non-sedating antihistamine, terfenadine, which is regarded as a 
positive control for torsades de pointes proarrhythmia assessment, in fact elicited torsades de 
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pointes in only a small proportion of patients prescribed the drug (Pugsley et al., 2008). 
Therefore the imperative to evolve a more predictive approach to proarrhythmia liability testing 
appears correct; however, the justification that animal models used in the assessment for drug-
induced proarrhythmia activity lack sensitivity is flawed. A lack of sensitivity in models is 
appropriate given the low risk of proarrhythmia in humans for all drugs, even drugs with 
established liability. The safety pharmacologist should recognize that the most important part of 
the problem is one of preclinical proarrhythmia bioassay sensitivity and specificity; particularly 
the ability to detect liability with a feasibly small number of experimental preparations. We make 
this point because the CiPA initiative, commendable though it is, may be attempting to solve the 
problem of detecting low risk liability by collecting multiple readouts all of which lack specificity – 
because risk is low, not because the magical formula of multiple target effect profile has not yet 
been identified (Authier et al., 2010). This would all be inconsequential were it not for the fact 
that proarrhythmia (especially production of torsades de pointes) can be lethal.  
The current survey identified PVCs as the most frequently reported arrhythmia type, 
especially in large animal species used in the conduct of standard SP studies. However, the 
survey did not explore the subtype of arrhythmia specifically defined as a PVC. However, 
because these arrhythmias are commonly observed with a prevalence estimated between 1-4% 
in humans (Kennedy et al., 1985) and because it is conceivable that they may respond 
differently to drugs, it is usually prudent to define their nature (Curtis et al., 2013). More serious 
ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation were reported 
in all species, especially in dogs, likely also due to their frequent use in cardiac safety studies 
(Lindgren et al., 2008). When compared to other species, the proportion of responders that 
observed AVB in dogs was much higher than that in other species.  While most responders 
considered that human stem cell derived or iPSC cardiomyocytes were a valuable addition to 
the overall proarrhythmia screening assay, potential limitations to their use appeared to include 
reliability of the cells to represent adult cardiomyocyte phenotypes, cardiac ion channel 
expression stability, and financial considerations. It appears that a certain apprehension within 
the SP community remains in the implementation of this assay beyond validation. 
A large proportion of responders (40%) acknowledged that the actual predictive value of 
nonclinical safety assays for the clinical TQT response has not been formally evaluated. 
However, publications have addressed the predictive value of QTc measurements in beagle 
dogs, if not for the TQT outcome, then for QT effects in humans.  Ollerstam et al. (2006) 
explored the PK-PD relationships for QTc prolongation by dofetilide in dogs and humans.  This 
approach has been extended to a larger number of compounds (Parkinson et al., 2013).  Ewart 
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et al. (2013) showed very good concordance between dog and human QTc effects for 150 
proprietary compounds from 12 pharmaceutical companies.  Furthermore, the Health and 
Environmental Sciences Institute (HESI) Pro-Arrhythmia Working Group recently published a 
paper (Vargas et al., 2015) that identified both human and non-rodent animal studies that 
assessed QT signal concordance between species, based on 40 marketed drugs.  The study 
primarily found that QT interval data derived from relevant non-rodent models had a 90% 
chance of predicting QT ﬁndings in humans. However, the perception revealed by this survey 
highlights the need for CiPA to assemble all the available published data on concordance 
between nonclinical (in silico, in vitro and in vivo) assays/models in order to critically evaluate 
current non-clinical assays, evaluate drugs with broad ion channel blocking characteristics and 
derive data-driven recommendations for use. 
The anticipated utilization of the CiPA assay differed between responders as some 
considered it would be better used as a screening tool (56%), while others considered its 
implementation at the lead stage of drug development (42%) or as part of the FIH package 
(34%). As the initiative progresses, it is hoped that the CiPA assay is able to impact drug 
development efforts and better establish a framework to guide proarrhythmia risk assessment. 
To this effect it is worth mentioning that during the ICH Assembly meeting held in Jacksonville, 
FL on December 9-10, 2015, the decision was taken to reopen the ICH S7B and E14 
Discussion Group with the objective to review emerging data that may influence the content of 
both ICH S7B and E14 in the future (Anonymous, 2016). 
Survey limitations included the potential participation of several employees from the same 
organization. The response rate (i.e. 10%) was lower than other recent industry surveys 
undertaken by the SPS but was comparable to the previous survey on the same topic. The 
lower response rate may be explained by the specialized nature of CiPA related assays.  
5. Conclusion 
 
Proarrhythmia liability assessment in drug development presently includes study types 
consistent with CiPA. It is anticipated that CiPA will develop into a workable solution to the 
concern that proarrhythmia liability testing remains suboptimal. The main anticipated value, 
however, is to avoid falsely identifying drugs as unsafe that in fact are safe in humans (Wallis, 
2010; Gintant et al., 2016), although examples of such drugs in current use are limited to 
verapamil, ranolazine and alfuzosin. This is rather different from developing a more sensitive 
integrated approach for detecting proarrhythmia liability. It is important the two are not confused. 
The present survey indicates that current practice has yet to assimilate this disconnect. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2016 JPTM  
2/16/2017 
13 
 
Acknowledgement 
The authors want to thank the Safety Pharmacology Society (SPS) for support in the conduct of 
this survey. 
Conflict of Interest 
None of the authors have any conflicts of interest, other than their employment in commercial 
pharmaceutical companies, academic institutions, or contract research organizations. No 
information is presented in this paper that advocates for or promotes commercial products from 
any of our organizations.   
 
References 
 
Anonymous, Meeting Report ICH Assembly, 9 – 10 December 2015, Jacksonville, FL, USA, 
http://www.ich.org/fileadmin/Public_Web_Site/Meetings/BSC_Reports/Assembly_report_Jackso
nville_2015.pdf (Accessed on January 26, 2017).  
 
Authier, S., Arezzo, J., Delatte, M.S., Kallman, M.J., Markgraf, C., Paquette, D., Pugsley, M.K., 
Ratcliffe, S., Redfern, W.S., Stevens, J., Valentin, J.-P., Vargas, H.M., Curtis, M.J. (2016). 
Safety pharmacology investigations on the nervous system: An industry survey. Journal of 
Pharmacological and Toxicological Methods, 81, 37-46. 
 
Authier, S., Pugsley, M.K., Troncy, E., Curtis, M.J. (2010). Arrhythmogenic liability screening in 
cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology 
and clinical thorough QT (TQT) studies. Journal of Pharmacological and Toxicological Methods, 
62, 83-88. 
 
Authier, S., Vargas, H.M., Curtis, M.J., Holbrook, M., Pugsley, M.K. (2013). Safety 
pharmacology investigations in toxicology studies: an industry survey. Journal of 
Pharmacological and Toxicological Methods, 68, 44-51. 
 
Brüggemann, A., Stoelzle, S., George, M., Behrends, J.C., Fertig, N. (2006). Microchip 
technology for automated and parallel patch-clamp recording. Small, 2, 840-846. 
 
Cavero I, Holzgrefe H, Clements M. (2016). The prospective IQ-CSRC trial: A prototype early 
clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) 
study. Journal of Pharmacological and Toxicological Methods, 80, 1-8. 
 
Cheung, P.H., Pugsley, M.K., Walker, M.J. (1993). Arrhythmia models in the rat.  Journal of 
Pharmacological and Toxicological Methods. 29, 179-184. 
 
Chow GV, Marine JE, Fleg JL. (2012). Epidemiology of arrhythmias and conduction disorders in 
older adults. Clinical & Geriatric Medicine, 28, 539-553. 
 
Colatsky, T., Fermini, B., Gintant, G., Pierson, J., Sager, P., Strauss, D.G., Sekino, Y., & 
Stockbridge, N. (2016). The Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative - 
Update on Progress.  Journal of Pharmacological and Toxicological Methods, 81, 15-20. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2016 JPTM  
2/16/2017 
14 
 
 
Comley, J. (2014).  Automated patch clamping finally achieves high throughout!  Drug Discovery 
World, 45-56. 
 
Cranefield PF, Aronson RS. (1988). Torsade de pointes and other pause-induced ventricular 
tachycardias: the short-long-short sequence and early afterdepolarizations. Pacing & Clinical 
Electrophysiology, 11, 670-678. 
 
Crumb, W.J. Jr., Vicente, J., Johannesen, L., Strauss, D.G. (2016). An evaluation of 30 clinical 
drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel 
panel. Journal of Pharmacological and Toxicological Methods, 81, 251-62. 
 
Curtis, M.J., Hancox, J.C., Farkas, A., Wainwright, C.L., Stables, C.L., Saint, D.A., Clements-
Jewery, H., Lambiase, P.D., Billman, G.E., Janse, M.J., Pugsley, M.K., Ng, G.A., Roden, D.M., 
Camm, A.J. & Walker, M.J.A.  (2013). The Lambeth Conventions (II): guidelines for the study of 
animal and human ventricular and supraventricular arrhythmias.  Pharmacology & Therapeutics, 
139, 213-248. 
 
Day, C.P., McComb, J.M., Campbell, R.W. (1990).  QT dispersion: an indication of arrhythmia 
risk in patients with long QT intervals. British Heart Journal, 63, 342-344. 
 
Ewart, L., Aylott, M., Deurinck, M., Engwall, M., Gallacher, D.G., Geys, H. et al. (2014). The 
concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-
company data sharing initiative. Toxicological Sciences, 142, 427–435. 
 
Fermini, B., Hancox, J.C., Abi-Gerges, N., Bridgland-Taylor, M., Chaudhary, K.W., Colatsky, T., 
Correll, K., Crumb, W., Damiano, B., Erdemli, G., Gintant, G., Imredy, J., Koerner, J., Kramer, 
J., Levesque, P., Li, Z., Lindqvist, A., Obejero-Paz, C.A., Rampe, D., Sawada, K., Strauss, D.G., 
Vandenberg, J.I. (2016). A new perspective in the field of cardiac safety testing through the 
Comprehensive In Vitro Proarrhythmia Assay paradigm. Journal of Biomolecular Screening, 21, 
1-11. 
 
Friedrichs, G.S., Patmore, L., Bass, A. (2005).  Non-clinical evaluation of ventricular 
repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies 
Journal of Pharmacological and Toxicological Methods, 52, 6-11. 
 
Guo, L., Coyle, L., Abrams, R.M., Kemper, R., Chiao, E.T., Kolaja, K.L. (2013). Refining the 
human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicological Science, 136, 
581-594. 
 
Gauvin, D.V., Tilley, L.P., Smith, F.W. Jr., Baird, T.J. (2009). Spontaneous cardiac arrhythmias 
recorded in three experimentally- and drug-naive laboratory species (canine, primate, swine) 
during standard pre-study screening. Journal of Pharmacological and Toxicological Methods, 
59, 57-61. 
 
Gintant, G., Sager, P.T., Stockbridge, N. (2016). Evolution of strategies to improve preclinical 
cardiac safety testing. Nature Reviews Drug Discovery, 15, 457-471. 
 
Hagerty, M.J., Wainwright, C.L., Kane, K.A. (1996). The in-vivo cardiovascular effects of a 
putative class III anti-arrhythmic drug, AM 92016. Journal of Pharmacy & Pharmacology, 48, 
417-421. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2016 JPTM  
2/16/2017 
15 
 
 
Hamill, O.P., Marty, A., Neher, E., Sakmann, B., Sigworth, F.J. (1981). Improved patch-clamp 
techniques for high-resolution current recording from cells and cell-free membrane patches. 
Pflugers Archives, 391, 85-100. 
 
Hammond, T.G., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Redfern, W.S., Sullivan, 
A.T., Camm, A.J. (2001). Methods of collecting and evaluating non-clinical cardiac 
electrophysiology data in the pharmaceutical industry: results of an international survey. 
Cardiovascular Research, 49, 741-750. 
 
Himmel, H.M. (2013). Drug-induced functional cardiotoxicity screening in stem cell-derived 
human and mouse cardiomyocytes: effects of reference compounds. Journal of 
Pharmacological and Toxicological Methods, 68, 97-111. 
 
Hondeghem, L.M., Carlsson, L., Duker, G. (2001). Instability and triangulation of the action 
potential predict serious proarrhythmia, but action potential duration prolongation is 
antiarrhythmic. Circulation, 103, 2004-2013. 
 
Huang, H., Pugsley, M.K., Fermini, B., Curtis, M.J., Koerner, J., Accardi, M., Authier, S. (2016) 
Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to 
the CiPA initiative (Submitted to Journal of Pharmacological and Toxicological Methods) 
 
Huikuri, H.V., Castellanos, A., Myerburg, R.J. (2001). Sudden death due to cardiac arrhythmias. 
New England Journal of Medicine, 345, 1473-1482. 
 
Johannesen, L., Vicente, J., Mason, J.W., Sanabria, C., Waite-Labott, K., Hong, M., Guo, P., 
Lin, J., Sørensen, J.S., Galeotti, L., Florian, J., Ugander, M., Stockbridge, N., Strauss, D.G. 
(2014).  Differentiating drug-induced multichannel block on the electrocardiogram: randomized 
study of dofetilide, quinidine, ranolazine, and verapamil. Clinical Pharmacology & Therapeutics, 
96, 549-558. 
 
Kennedy, H.L., Whitlock, J.A., Sprague, M.K., Kennedy, L.J., Buckingham, T.A., Goldberg, R.J. 
(1985). Long-term follow-up of asymptomatic healthy subjects with frequent and complex 
ventricular ectopy. New England Journal of Medicine, 312, 193-197. 
 
Kirby, R.J., Qi, F., Phatak, S., Smith, L.H., Malany, S. (2016). Assessment of drug-induced 
arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte 
contractility. Toxicology & Applied Pharmacology, 305, 250-258. 
 
Kramer, J., Obejero-Paz, C.A., Myatt, G., Kuryshev, Y.A., Bruening-Wright, A., Verducci, J.S. & 
Brown, A.M. (2013). MICE models: superior to the HERG model in predicting Torsade de 
Pointes. Scientific Reports 3, 2100. doi: 10.1038/srep02100 
 
Lepple-Wienhues, A., Ferlinz, K., Seeger, A., Schäfer, A. (2003). Flip the tip: an automated, 
high quality, cost-effective patch clamp screen. Receptors & Channels, 9, 13-17. 
 
Lawrence, M. Bridgeland-Taylor, C.L., Pollard, C.E., Hammond, T.G., Valentin, J.P. (2006). A 
rabbit Langendorff heart proarrhythmia model: predictive value for clinical hazard identification 
and safety margins. British Journal of Pharmacology, 149, 845-860. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2016 JPTM  
2/16/2017 
16 
 
Lindgren, S., Bass, A.S., Briscoe, R., Bruse, K., Friedrichs, G.S., Kallman, M.J., Markgraf, C., 
Patmore, L., Pugsley, M.K. (2008). Benchmarking safety pharmacology regulatory packages 
and best practice Journal of Pharmacological and Toxicological Methods, 58, 99-109. 
 
Mirams, G.R., Cui, Y., Sher, A., Fink, M., Cooper, J., Heath, B.M., McMahon, N.C., Gavaghan, 
D.J., Noble, D. (2011) Simulation of multiple ion channel block provides improved early 
prediction of compounds’ clinical torsadogenic risk. Cardiovascular Research, 91, 53-61. 
 
Navarrete, E.G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., 
Burridge, P.W., Patlolla, B., Lee, A.S., Wu, H., Beygui, R.E., Wu, S.M., Robbins, R.C., Bers, 
D.M., Wu, J.C. (2013). Screening drug-induced arrhythmia [corrected] using human induced 
pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. 
Circulation, 128, S3-S13. 
 
Obergrussberger, A., Stölzle-Feix, S., Becker, N., Brüggemann, A., Fertig, N., Möller, C. (2015). 
Novel screening techniques for ion channel targeting drugs. Channels (Austin), 9, 367-375. 
 
O'Hara, T., Rudy, Y. (2012). Quantitative comparison of cardiac ventricular myocyte 
electrophysiology and response to drugs in human and nonhuman species. American Journal of 
Physiology, 302, H1023-H1030. 
 
Okada, J., Yoshinaga, T., Kurokawa, J., Washio, T., Furukawa, T., Sawada, K., Sugiura, S., 
Hisada, T. (2015). Screening system for drug-induced arrhythmogenic risk combining a patch 
clamp and heart simulator. Science Advances, 1, e1400142. 
 
Ollerstam, A., Visser S.A.G., Persson, A.H., Eklund, G., Nilsson, L.B., Forsberg, T., Wiklund, 
S.J., Gabrielsson, J., Duker, G., Al-Saffar, A. (2006) Pharmacokinetic-pharmacodynamic 
modeling of drug-induced effect on the QT interval in conscious telemetered dogs. Journal of 
Pharmacological and Toxicological Methods, 53, 174–183. 
 
O'Mahony, C., Elliott, P., McKenna, W. (2013). Sudden cardiac death in hypertrophic 
cardiomyopathy. Circulation Arrhythmias & Electrophysiology, 6, 443-451. 
 
Parkinson, J., Visser, S.A.G., Jarvis, P., Pollard, C., Valentin, J-P., Yates, J.W.T., Ewart, L. 
(2013) Translational pharmacokinetic–pharmacodynamic modeling of QTc effects in dog and 
human. Journal of Pharmacological and Toxicological Methods, 68, 357–366. 
 
Pollard, C.E., Abi Gerges, N., Bridgland-Taylor, M.H., Easter, A., Hammond, T.G., Valentin, J.P. 
(2010). An introduction to QT interval prolongation and non-clinical approaches to assessing 
and reducing risk. British Journal of Pharmacology, 159, 12-21. 
 
Polonchuk, L. (2012).  Toward a New Gold Standard for Early Safety: Automated Temperature-
Controlled hERG Test on the PatchLiner. Frontiers in Pharmacology, 26, 3. 
 
Pugsley, M.K., Authier, S., Curtis, M.J. (2008).  Principles of Safety Pharmacology. British 
Journal of Pharmacology, 154, 1382-1399. 
 
Qato, D.M., Wilder, J., Schumm, L.P., Gillet, V., Alexander, G.C. (2016). Changes in 
prescription and over-the-counter Medication and dietary supplement use among older adults in 
the United States, 2005 vs 2011. Journal of the American Medical Association, 176, 473-482. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2016 JPTM  
2/16/2017 
17 
 
Qu, Y., Gao, B., Fang, M., Vargas, H.M. (2013). Human embryonic stem cell derived cardiac 
myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization 
delay. Journal of Pharmacological and Toxicological Methods, 68, 74-81. 
 
Qu, Y., Vargas, H.M. (2015). Proarrhythmia risk assessment in human induced pluripotent stem 
cell-derived cardiomyocytes using the Maestro MEA platform. Toxicological Science, 147, 286-
295. 
 
Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Palethorpe, S., Siegl, 
P.K., Strang, I., Sullivan, A.T., Wallis, R., Camm, A.J., Hammond, T.G. (2003). Relationships 
between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de 
pointes for a broad range of drugs: evidence for a provisional safety margin in drug 
development. Cardiovascular Research, 58, 32-45. 
 
Rodriguez, B., Carusi, A., Abi-Gerges, N., Ariga, R., Britton, O., Bub, G., Bueno-Orovio, A., 
Burton, R.A.B., Carapella, V., Cardone-Noott, L., Daniels, M.J., Davies, M.R., Dutta, S., Ghetti, 
A., Grau, V., Harmer, S., Kopljar, I., Lambiase, P., Rong Lu, H., Lyon, A., Minchole, A., 
Muszkiewicz, A., Oster, J., Paci, M., Passini, E., Severi, S., Taggart, P., Tinker, A., Valentin, 
J.P., Varro, A., Wallman, M., Zhou, X. (2015). Human-based approaches to pharmacology and 
cardiology: an interdisciplinary and intersectorial workshop. Europace, 18, 1287-1298. 
 
Sager, P.T., Gintant, G., Turner, J.R., Pettit, S., & Stockbridge, N. (2014). Rechanneling the 
cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research 
Consortium.  American Heart Journal, 167, 292-300. 
 
Shah, R.R., Maison-Blanche, P., Robert, P., Denis, E., Duvauchelle, T. (2016). Can an early 
phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-
receptor antagonist/inverse agonist. European Journal of Clinical Pharmacology, 72, 533-543. 
 
Sigworth, F.J., Klemic, K.G. (2005). Microchip technology in ion-channel research. IEEE 
Transmissions in Nanobioscience, 4, 121-127. 
 
Stramba-Badiale, M., Nador, F., Porta, N., Guffanti, S., Frediani, M., Colnaghi, C., Grancini, F., 
Motta, G., Carnelli, V., Schwartz, P.J. (1997). QT interval prolongation and risk of life-
threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. 
American Heart Journal, 133, 108-111. 
 
US FDA (2005). ICH harmonized tripartite guideline S7B. Safety pharmacology assessment of 
the potential for delayed ventricular repolarization (QT interval prolongation) by human 
pharmaceuticals Available at: http://www.ich.org/cache/compo/276-254-1.html 
 
Valentin, J.P. (2010). Reducing QT liability and proarrhythmic risk in drug discovery and 
development. British Journal of Pharmacology, 159, 5-11. 
 
Valentin, J.P., Pollard, C., Lainée, P., Hammond, T. (2010). Value of non-clinical cardiac 
repolarization assays in supporting the discovery and development of safer medicines. British 
Journal of Pharmacology, 159, 25-33. 
 
Vargas, H.M., Bass, A.S., Koerner, J., Matis-Mitchell, S., Pugsley, M.K., Skinner, M., Burnham, 
M., Pettit, S., Valentin, J-P.  (2015). Evaluation of QTc prolongation in Animal and Human 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2016 JPTM  
2/16/2017 
18 
 
Studies: A Qualitative Assessment of Nonclinical and Clinical Concordance Based on the 
Literature. British Journal of Pharmacology, 172, 4002-4011. 
 
Vicente, J., Johannesen, L., Mason, J.W., Crumb, W.J., Pueyo, E., Stockbridge, N., Strauss, 
D.G. (2015). Comprehensive T wave morphology assessment in a randomized clinical study of 
dofetilide, quinidine, ranolazine, and verapamil. Journal of the American Heart Association, 4, 
pii: e001615. doi: 10.1161/JAHA.114.001615. 
 
Vicente, J., Stockbridge, N., Strauss, D.G. (2016). Evolving regulatory paradigm for 
proarrhythmic risk assessment for new drugs. Journal of Electrocardiology, pii: S0022-
0736(16)30095-4. doi: 10.1016/j.jelectrocard.2016.07.017 
 
Wakefield, I.D., Pollard, C., Redfern, W.S., Hammond, T.G., Valentin, J.-P. (2002). The 
application of in vitro methods to safety pharmacology. Fundamentals of Clinical Pharmacology, 
16, 209-218. 
 
Wallis, R.M. (2010).  Integrated risk assessment and predictive value to humans of non-clinical 
repolarization assays. British Journal of Pharmacology, 159, 115-121. 
 
Wu, A.H., Das, S.K. (1999). Sudden death in dilated cardiomyopathy. Clinical Cardiology, 22, 
267-272. 
 
Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J.C., Robertson, G.A., January, C.T. (1998). 
Properties of HERG channels stably expressed in HEK 293 cells studied at physiological 
temperature. Biophysics Journal, 74, 230-241. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2016 JPTM  
2/16/2017 
19 
 
Figures 
Figure 1 – Proarrhythmia liability assessment and CiPA Survey Demographics 
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Panel E 
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Panel G 
 
 
Figure 1 – Panels A-G describe the characteristics of those responding to the survey in terms of 
expertise (A), geographical location (B), organization affiliation (C), size of the organization (D), 
indication most frequently targeted by drugs developed from 2011 to 2016 (69 respondents) (E) 
and role in the conduct of in silico assays (F) and in vitro assays (G). 
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Figure 2 Applications of in vitro assays in the assessment of cardiovascular liabilities 
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Figure 3 Number of test article concentrations used to determine drug potency (IC50) 
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Figure 4 The percent of responders that calculate confidence intervals for IC50 values when 
conducting in vitro ion channel assays 
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Figure 5 The impact of hERG channel blockade on pharmacophore development  
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Tables 
 
Table 1 Nonclinical approaches used to address proarrhythmia issues 
 
What best describes the nonclinical approach used to address proarrhythmia issues in your company?* 
Answer Options 
Response 
Percent 
Response 
Count 
Conduct a battery of in vitro (i.e., binding studies, ion channel studies, etc.), 
and in vivo CV safety pharmacology assays to screen drug candidates and 
establish risk during drug discovery 
75% 58 
   
Conduct “fit-for-purpose” nonclinical safety pharmacology tests based on an 
integration of observations derived from chemistry (SAR), Toxicology 
findings and other scientific considerations (e.g., drug indication, drug class, 
pharmacology, PK/PD etc.) 
31% 24 
   
Perform safety testing based on GLP findings from safety pharmacology 
and toxicology studies only 
20% 15 
   
I do not know 4% 3 
 
* Responders selected all that applied.  
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Table 2 Cardiovascular assays used by the pharmaceutical industry 
 
Which of the following cardiac/cardiovascular assays has your company used in the last 5 years?  
Answer Options 
Frequently 
used 
Rarely 
used 
Response Count 
Cell lines stably expressing ion channels for 
determination of drug block potency 
89% 11% 66 
ECG recording using Implanted telemetry 
technology 
88% 12% 67 
Jacketed External Telemetry (JET) 62% 38% 63 
Ion channel Binding assays 57% 43% 68 
Anesthetized animal models 53% 47% 58 
Cardiac Action Potential recordings (e.g., Purkinje 
fiber, papillary muscle, others…) 
51% 49% 61 
Human stem cell-derived or induced pluripotent 
stem cell cardiomyocytes (iPSC-CM) 
46% 54% 68 
hERG (IKr) channel trafficking 42% 58% 72 
Isolated Tissue bath preparations 41% 59% 63 
Isolated Langendorff heart 38% 62% 63 
Isolated cardiac wedge preparation 18% 82% 51 
Proarrhythmia animal models 12% 88% 49 
Zebrafish assays 4% 96% 47 
 
* Responders selected all that applied.  
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Table 3 Conduct of In silico studies 
 
Does your company conduct in silico studies? (Used in the last 5 years or Routinely used)* 
Answer Options Never Used Rarely Used 
Frequently 
Used 
Response 
Count 
In silico studies are used to 
evaluate drug effect on hERG 
35% 32% 33% 79 
In silico studies are used to 
evaluate drug effect on the 
Cardiac Action Potential 
42% 42% 15% 78 
In silico studies are __________ 
(fill in the blank with 
checkboxes) in my assessment 
of drug safety 
39% 38% 23% 71 
In silico studies are used to evaluate other effects (Please specify) 
- Genetic toxicity (6) 
- Effects on other CV ion channels (2) 
- Brain penetration (2) 
- Others (9) 
19 
 
* Responders selected all that applied.  
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Table 4 Time of the conduct of in silico (ion channel and AP) and in vitro cardiac 
electrophysiology assays 
 
Panel A  
What best describes the timing of in silico (ion channel or AP) modeling assays conducted by your company?* 
Answer Options 
Response 
Percent 
Response 
Count 
In silico modeling assays are not used by my company 44% 33 
In silico assays are conducted early in drug discovery 43% 32 
In silico assays are conducted before any nonclinical data is obtained 17% 13 
In silico assays are conducted during drug development (i.e., after compound 
nomination) 
13% 10 
In silico assays are conducted during nonclinical GLP studies 12% 9 
In silico assays are conducted after Phase 1 clinical trials 1% 1 
 
Panel B 
What best describes the timing of in vitro ion channel electrophysiology assays conducted by your company?* 
Answer Options 
Response 
Percent 
Response 
Count 
In vitro electrophysiology assays are not used by my company 7% 5 
In vitro assays are conducted early in drug discovery/before nonclinical data is 
obtained 
80% 61 
In vitro assays are conducted during drug development (i.e. after compound 
nomination/selection) 
40% 30 
In vitro assays are conducted during nonclinical GLP studies 30% 23 
In vitro assays are conducted after Phase 1 clinical trials 3% 2 
 
* Responders selected all that applied. 
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Table 5 The in vitro ion channel testing procedures used 
 
Please define the in vitro ion channel testing procedures used in your organization:* 
Answer Options 
Response 
Percent 
Response 
Count 
Positive control included for each study 82% 63 
Washout data obtained 43% 33 
GLP compliant  48% 37 
Manual patch clamp 71% 55 
Automated patch clamp 75% 58 
Test conducted at room temperature  71% 55 
Test conducted at physiological temperature 58% 45 
 
* Responders selected all that applied. 
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Table 6 Cardiac ion channels tested when using stably expressed cell lines  
 
If you are using cell lines with stably expressed ion channels, which of the following have you tested in the last 5 
years and which ion channels are routinely tested?* 
Answer Options 
Rarely 
Used 
Frequently 
Used 
Response 
Count 
INa/Nav1.5 (Sodium Channels) 23% 77% 65 
ICa,L/Cav1.2 (Calcium Channels) 20% 80% 64 
Ito,f/Kv4.3 (Fast Transient Outward Potassium Channel) 78% 22% 50 
IKur/Kv1.5 (Ultra-rapid Potassium Channel) 71% 29% 51 
Ito,s/Kv1.4 (Slow Transient Outward Potassium Channel) 84% 16% 44 
IKr/Kv11.1 (hERG) 9% 91% 67 
IKs/Kv7.1 (KvLQT1) 47% 53% 55 
IK1/Kir2.1-2.3 78% 22% 45 
Cav2.1 (P/Q Calcium Channel) 93% 8% 40 
Cav3.2 (T-type calcium Channel) 87% 13% 45 
HCN2 (K/Na hyperpolarization-activated pacemaker current) 95% 5% 41 
If/HCN4 (Prominent cardiac pacemaker ‘funny’ current) 80% 20% 45 
IKAch/(GIRK)Kir3.1/3.4 (G-protein coupled inward rectifying K channel) 88% 13% 40 
IKATP/Kir6.2/SUR2A (ATP-sensitive inward rectifying K channel) 95% 5% 39 
 
* Responders selected all that applied. 
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Table 7 Drugs used as positive controls for validation/qualification of cardiac ion channel assays 
 
Please indicate the control drugs used for ion channel assay validation/qualification 
in your organization in the last 5 years* 
Answer Options 
Response 
Percent 
Response 
Count 
Amiodarone 25% 20 
Amitriptyline 17% 14 
Astemizole 28% 23 
Bepridil 22% 18 
Cisapride 56% 45 
Clarithromycin 9% 7 
Diltiazem 27% 22 
Dofetilide 59% 48 
E-4031 65% 53 
Flecainide 53% 43 
Ibutilide 11% 9 
Imipramine 16% 13 
Loratidine 12% 10 
Quinidine 46% 37 
Mexilitine 27% 22 
Moxifloxacin 35% 28 
Nifedipine 59% 48 
Pentamidine 25% 20 
Pentobarbital 5% 4 
Pimozide 17% 14 
Procainamide 10% 8 
Sotalol 43% 35 
Terfenadine 52% 42 
Verapamil 62% 50 
I do not know 12% 10 
 
* Responders selected all that applied. 
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Table 8 Drugs used as positive controls for the interpretation and comparison to the test drug 
during the conduct of cardiac ion channel studies 
 
Please indicate the drugs that were used as positive controls for ion channel studies (interpretation and 
comparison with the test drug) in your organization in the last 5 years:* 
Answer Options 
Rarely 
Used 
Frequently 
Used 
Response 
Count 
Astemizole 70% 30% 33 
Bepridil 81% 19% 31 
Cisapride 44% 58% 43 
Clarithromycin 91% 9% 23 
Diltiazem 63% 37% 30 
Dofetilide 33% 67% 43 
E-4031 21% 79% 53 
Flecainide 38% 62% 42 
Ibutilide 88% 12% 25 
Imipramine 83% 17% 29 
Loratidine 85% 15% 26 
Quinidine 43% 57% 35 
Mexilitine 73% 27% 30 
Moxifloxacin 56% 44% 32 
Nifedipine 36% 64% 45 
Pentamidine 72% 28% 32 
Pentobarbital 84% 16% 25 
Pimozide 79% 21% 28 
Procainamide 78% 22% 27 
Sotalol 45% 55% 38 
Terfenadine 31% 69% 39 
Verapamil 28% 72% 43 
I do not know - - 12 
 
* Responders selected all that applied. 
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Table 9 hERG IC50 value variability for positive control drugs used in the assay  
 
Please estimate the variability (i.e., the range from lowest to highest value) in IC50 values that you have 
determined for hERG inhibition using the same positive control drug over the past year* 
Answer Options 
Response 
Percent 
Response 
Count 
I do not know 24% 18 
It was not formally evaluated 22% 17 
<25% 34% 26 
25-75% 13% 10 
75-100% 4% 3 
100-200% 1% 1 
>200% 1% 1 
 
* Responders selected all that applied. 
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Table 10 Use of a positive control drug during the conduct of in vitro ion channel assays 
 
When using a positive control drug in an in vitro ion channel assay, how is the positive control utilized?* 
Answer Options 
Response 
Percent 
Response 
Count 
To determine if the assay responds appropriately by using a supramaximal 
concentration of the positive control 
66% 47 
To determine assay sensitivity by using a concentration of the positive 
control that is similar to its IC50 value 
49% 35 
A positive control drug is not used in ion channel assays 3% 2 
 
* Responders selected all that applied. 
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Table 11 Positive control drugs selected for use in cardiac ion channel studies 
 
Please indicate how positive control drugs are selected for ion channel studies: 
Answer Options 
Response 
Percent 
Response 
Count 
We always include the same positive control drugs 79% 60 
We select positive control drugs based on chemistry of the compound to test 13% 10 
We select positive controls based on the therapeutic indication of the compound to test 7% 5 
We select positive controls to include comparator/similar drugs to the compound to test 22% 17 
 
* Responders selected all that applied. 
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Table 12 Types of arrhythmia observed in nonclinical studies 
 
Have you encountered drug induced arrhythmia in nonclinical studies?* 
  Rat Guinea Pig Rabbit Dog Pig 
Non-human 
Primates 
Response 
Count 
I don't know 74% 68% 71% 68% 74% 58% 31 
Premature ventricular 
contractions (PVCs) 
15% 17% 29% 80% 15% 59% 41 
Ventricular tachycardia 24% 27% 39% 79% 12% 58% 33 
Ventricular fibrillation 23% 27% 36% 55% 14% 55% 22 
Atrioventricular (AV) block 14% 32% 20% 77% 7% 41% 44 
 
* Responders selected all that applied. 
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Table 13 Use of human stem cell derived or iPSC cardiomyocytes 
 
In your view, human stem cell derived or iPSC cardiomyocytes are: * 
Answer Options 
Response 
Percent 
Response 
Count 
Representative of adult cardiomyocytes and provide reliable data as a nonclinical 
safety assay 
21% 15 
A valuable addition to the proarrhythmia screening assays 75% 54 
Can replace cell lines with stable expression of human ion channels 17% 12 
Have a stable expression of cardiac ion channels in culture to provide reliable data 19% 14 
Are economically valuable to be added to proarrhythmia assays 26% 19 
I do not know 13% 9 
 
* Responders selected all that applied. 
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Table 14 Predictivity of nonclinical safety assays for the clinical (TQT) response  
 
Please estimate the predictivity for clinical responses (e.g., TQT) of the nonclinical safety assays used in your 
organization when considering integrated QT risk assessment:* 
Answer Options 
Response 
Percent 
Response 
Count 
It was not formally evaluated 40% 30 
Is 60-75% 9% 7 
Is 75-90% 21% 16 
Is >90% 15% 11 
I do not know 21% 16 
 
* Responders selected all that applied. 
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Table 15 Anticipated use of the CiPA ion channel assay 
 
How do you anticipate using the CiPA ion channel assays?* 
Answer Options 
Response 
Percent 
Response 
Count 
As a screening tool 56% 44 
At the lead development stage 42% 33 
As part of the FIH package 34% 27 
Strictly as indicated by the regulatory agencies (check box exercise) 17% 13 
I do not know 13% 10 
 
* Responders selected all that applied. 
